Adaptimmune Therapeutics PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Long Focus Capital Management and John Helmers have reported a 0% beneficial ownership stake in Adaptimmune Therapeutics PLC as of December 31, 2025.
Two Seas Capital LP and its affiliates have reported a complete divestment of their holdings in Adaptimmune Therapeutics PLC, now owning 0% of the company's ordinary shares.
EcoR1 Capital and its affiliates have reduced their beneficial ownership in Adaptimmune Therapeutics PLC to below 5% of the outstanding Ordinary Shares.
Two Seas Capital LP and its affiliates have increased their beneficial ownership in Adaptimmune Therapeutics PLC to 8.5% of ordinary shares as of June 30, 2025.
Two Seas Capital LP, along with its general partner and chief investment officer, has reported a passive 8% beneficial ownership stake in Adaptimmune Therapeutics PLC.
Two Seas Capital LP, along with its general partner Two Seas Capital GP LLC and managing member Sina Toussi, has disclosed a passive 5.8% beneficial ownership stake in Adaptimmune Therapeutics PLC.
SCHEDULE 13G/A: Baillie Gifford & Co Discloses Reduced Passive Stake in Adaptimmune Therapeutics PLC
Baillie Gifford & Co has reported a 4.6% passive ownership stake in Adaptimmune Therapeutics PLC as of December 31, 2024, indicating a reduction below the 5% threshold.
SCHEDULE 13G/A: Long Focus Capital Management and Affiliates Disclose 8.0% Passive Stake in Adaptimmune Therapeutics PLC
Long Focus Capital Management, LLC, along with its affiliates and individuals John and Glenn Helmers, have disclosed a combined passive beneficial ownership of 8.0% in Adaptimmune Therapeutics PLC as of December 31, 2024.
Matrix Capital Management Company LP and David E. Goel have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Adaptimmune Therapeutics plc as of December 31, 2024.